HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 9, September 2016 – Infectious Diseases       » Curcumin Derivatives May Prevent Alzheimer's Disease by Promoting Amyloid- Clearance       » Varian Chosen to Equip First Government Owned Proton Centre in China       » Medtronic and SingHealth Collaborate on a Centre of Excellence to Fight Diabetes       » NCCS Awards Contract for Proton Beam Therapy System to Hitachi Asia      
INSIDE INDUSTRY
Debiopharm Group (TM) to expand activities at manufacturing facility in Switzerland

Debiopharm GroupTM (Debiopharm), a Swiss-based global biopharmaceutical group of companies has decided to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field.

Debiopharm Research & Manufacturing S.A. boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate the facility and increase its industrial capacity. The objective is to expand industrial operations in Martigny by acquiring opportunities for optimization and production, generating a double-digit million revenue annually. Expertise in R&D and manufacturing of hard-to-make pharmaceutical products, modern infrastructure combined with high-tech GMP-compliant production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe are some of the features that will enable this objective to be met.

"We want to be the bridge between development and industrialization," says Cedric Sager, Chief Executive Officer of Debiopharm Research & Manufacturing S.A., "and supply Swiss-made products manufactured using state-of-the-art technology. Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list."

Thierry Mauvernay, Delegate of the Board of Debiopharm Group, explains that "we have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development".

Source: PR Newswire

Click here for the complete issue.

NEWS CRUNCH  
news Enterprise meets technology: More than 300 enabling innovations showcased at TechInnovation
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Orthopaedics
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy